Category: Press Releases

Genprex’s CEO participates in a live interview with the “Big Biz Show” for a second time, providing details on its lead drug candidate for NSCLC, its diabetes gene therapy and what lies ahead in the next 18 months in the midst of COVID-19.

Grant to fund ongoing preclinical research for important proof-of-principle non-human studies in preparation for human gene therapy clinical trials

Genprex was added to the Russell 3000® Index after the market closed on Friday, June 26, 2020 as part of the 2020 Russell U.S. Indexes reconstitution.

Company executes on corporate communication strategy and advances drug branding initiatives

Rodney Varner will be participating in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show, on Thursday, June 25.

Expansion enables full commercial scale plasmid DNA manufacturing capabilities

Genprex is scheduled to join the U.S. broad-market Russell 3000 Index when FTSE Russell, a leading global index provider, reconstitutes its 2020 indices after the markets close on Friday, June 26.

Mr. Varner will deliver an overview of the Company and provide updates on its product pipeline.

The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.

New license agreement expands Genprex’s oncology franchise